SYGNIS AG Signs Distribution Agreement with LABGENE Scientific
News Sep 18, 2015
SYGNIS AG has announced that it has signed a distribution agreement with LABGENE Scientific for the commercialization of SYGNIS’ proprietary product portfolio in Switzerland.
Under the terms of the agreement, SYGNIS has granted LABGENE Scientific the rights to promote, market and sell all existing as well as future product lines to scientists working in genomics, proteomics and diagnostics in Switzerland.
These product lines cover the Company’s revolutionary TruePrime™ products for primer-free whole genome amplification (WGA) as well as SunScript™ thermostable reverse transcriptase kits for the translation of RNA into DNA including the newly launched SunScript™ One Step Reverse Transcriptase (RT)-PCR Kit for parallel transcription and amplification of genomic information.
LABGENE Scientific is a specialist provider offering a broad portfolio of advanced and high quality products, reagents and consumables for molecular biology laboratories and facilities as well as platforms as integrated solutions for the life science research, diagnostic laboratories and the pharmaceutical industry.
“We are very pleased about this distribution agreement for our proprietary product portfolio with LABGENE Scientific, a well established distributor in Switzerland. In addition to its very dynamic academic life science environment, Switzerland is the home to many biotechnology and pharmaceutical companies, including the biggest of the world, and an important market for our products in Europe. Today, more than 40 life science companies have their international headquarters in Switzerland,” Pilar de la Huerta, CEO and CFO of SYGNIS commented.
Huerta continued, “With its wide customer network, LABGENE Scientific is best positioned to leverage the benefits of our existing as well as future products to customers in academic and pharmaceutical molecular biology and diagnostics laboratories in Switzerland.”
CRISPR Screening Reveals Sickle Cell Disease TargetNews
A key signaling protein, known as heme-regulated inhibitor (HRI), has been identified as a potential therapeutic target for the development of drugs to treat sickle cell disease, using a CRISPR screening approach.READ MORE
DNA Methylation Related to Liver Disease in Obese PatientsNews
DNA methylation implicated in initiation of liver fibrosis in non-alcoholic fatty liver diseaseREAD MORE
UCL Technology Fund Investment MeiraGTx Raises $75 Million in IPONews
MeiraGTx Holdings plc raised $75 million of gross proceeds upon close of the company’s initial public offering (IPO).READ MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018